Evidence map›Paper›PMID 38469097›Full record

ArticleMolecular genetics and metabolism reports2024

Maximilian Breyer, Julia Grüner, Alexandra Klein, Laura Finke, Katharina Klug, Markus Sauer, Nurcan Üçeyler

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular genetics and metabolism reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maximilian BreyerDepartment of Neurology, University of Würzburg, 97080 Würzburg, Germany.
Julia GrünerDepartment of Neurology, University of Würzburg, 97080 Würzburg, Germany.
Alexandra KleinDepartment of Neurology, University of Würzburg, 97080 Würzburg, Germany.
Laura FinkeDepartment of Neurology, University of Würzburg, 97080 Würzburg, Germany.
Katharina KlugDepartment of Neurology, University of Würzburg, 97080 Würzburg, Germany.
Markus SauerDepartment of Biophysics and Biotechnology, Biocenter, University of Würzburg, 97074 Würzburg, Germany.
Nurcan ÜçeylerDepartment of Neurology, University of Würzburg, 97080 Würzburg, Germany.
University of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fabry disease (FD) is a life-limiting disorder characterized by intracellular globotriaosylceramide (Gb3) accumulations. The underlying α-galactosidase A (α-GAL A) deficiency is caused by variants in the gene

Indexed as

C.376 A > G (p.S126G)Disease modelFabry diseaseGlobotriaosylceramideInduced pluripotent stem cellsSensory neuronsVariants of unknown significanceα-Galactosidase A

Identifiers

PMID38469097
PMCPMC10926200
OpenAlexW4388994791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.